-+ 0.00%
-+ 0.00%
-+ 0.00%

Orchestra BioMed Q3 2026 net loss narrows 10% year over year to $18.75 million

PUBT·11/10/2026 21:28:41
Listen to the news
Orchestra BioMed Q3 2026 net loss narrows 10% year over year to $18.75 million
  • Orchestra BioMed’s third-quarter 2026 net loss attributable to common stockholders narrowed 6% year-over-year to $19.6 million.
  • Revenue dropped 89% year-over-year to $91,000, while research and development expenses rose 26% to $17.7 million.
  • A public offering closed November 9 raised $80.5 million in net proceeds, extending projected cash runway through 2028.
  • The BACKBEAT pivotal trial of AVIM Therapy completed enrollment with 349 patients randomized, exceeding its target.
  • Primary endpoint results are planned for submission for late-breaking presentation at HRS 2027, with Medtronic’s regulatory filing contingent on positive results.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101610PRIMZONEFULLFEED9874892) on November 10, 2026, and is solely responsible for the information contained therein.